Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects

NCT05095168 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

PNH

Interventions

DRUG: CAN106
DRUG: Placebo

Sponsor

CARE Pharma Shanghai Ltd.